Scientific deep-dive

GLP-1 Drugs and Low Blood Sugar: Who Is Actually at Risk

A GLP-1 alone is a poor cause of hypoglycemia, because it prompts insulin only when glucose is already high. The risk belongs to what it is taken alongside, and the label says one combination has never been evaluated.

By Ruth Calder · Enforcement Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed
6 min read·4 citations

If a GLP-1 is the only glucose-lowering drug you take, low blood sugar is an unlikely problem. These drugs prompt insulin release in response to glucose, so when glucose is not high they largely stop prompting. The risk arrives with what sits beside them. The Wegovy label is explicit about which company it keeps: put a sulfonylurea, or insulin, in the picture and hypoglycemia becomes more likely. It tells prescribers to consider cutting that other dose at the point the GLP-1 starts.[1] Metformin is not on that list; where it does overlap with a GLP-1 is covered in metformin and a GLP-1 together.

Why the mechanism matters here

Insulin, and the sulfonylureas the label groups as insulin secretagogues, lower blood glucose whether or not it needs lowering. That is what makes them capable of driving it too far down. A GLP-1 works differently: its effect on insulin secretion is glucose-dependent, which is the technical way of saying it largely stands down when glucose is normal.

The largest ongoing comparison of diabetes medicines, a living network meta-analysis in the BMJ updated at least twice a year, reflects that. It names sulfonylureas, insulin and DPP-4 inhibitors as probably increasing the risk of severe hypoglycemia.[2] GLP-1 receptor agonists are not in that list. In one trial, swapping basal-bolus insulin for a weekly semaglutide and insulin icodec injection cut serious lows by 88%. (Why a DPP-4 inhibitor such as Januvia is usually stopped when a GLP-1 starts is set out in Januvia and a GLP-1 together.)

Insulin and sulfonylureas lower blood glucose whether or not it needs lowering; a GLP-1 largely stands down when glucose is normal.

What the label actually counted

“Unlikely” is not “never”, and the label does not pretend otherwise. In its trial of adults who had type 2 diabetes alongside a BMI of 27 or above, hypoglycemia (defined as plasma glucose below 54 mg/dL) was reported in more patients on Wegovy than on placebo. One episode of severe hypoglycemia, meaning it required another person’s help, occurred in a treated patient, against none on placebo.[1]

One episode is a small number, but it is not zero, and it comes from the population where this matters: people who have diabetes as well as excess weight, and who are therefore likely to be on other glucose-lowering drugs already.

If you do not have diabetes and take nothing else for glucose, this page is mostly reassurance. The trials in that population do not show meaningful hypoglycemia, and the mechanism explains why. Learn the symptoms anyway, and come back to this the moment any other glucose-lowering drug is added. An over-the-counter glucose sensor will not warn you of a low; see what CGMs can and cannot do without diabetes.

The combination the label has not tested

One sentence in the label is easy to read past. It states that the use of Wegovy in patients with type 1 diabetes, or in combination with insulin, has not been evaluated.[1]

That is not a contraindication or a warning against it. It means untested, and the difference matters because people reasonably assume that an approved drug has been studied in the combination they are personally taking. The sentence is about Wegovy’s own trials, though, not the whole class. Someone taking Wegovy with insulin is outside what those trials examined, whatever their prescriber has concluded is right for them. At diabetes doses the combination has been studied: the Ozempic and Mounjaro labels each report a trial that added the drug to basal insulin in type 2 diabetes, with hypoglycemia counted.[3][4]

What the label asks a prescriber to do

  1. Check glucose before starting, and during. For patients with diabetes the label asks for monitoring at both points, not just afterward.[1]
  2. Consider a smaller dose of the sulfonylurea or insulin from the day the GLP-1 begins. The label frames this as something to weigh when the GLP-1 starts, rather than a change to make after a low reading.[1]
  3. Teach the symptoms. The label asks prescribers to inform patients of the risk and educate them on the signs, which implies you should have been told and can ask if you were not.
We are not going to tell you how much to reduce anything by. The label says “consider reducing” without naming a figure, because it depends on which drug, what dose, and your own readings. That is a prescriber’s judgment, and it is the conversation to have before the first GLP-1 injection rather than after the first low reading. Our titration planner will print your drug’s own schedule so you can take a dated plan into that appointment.

Knowing it when it happens

Shakiness, sweating, a racing heart, sudden hunger, confusion, irritability or difficulty concentrating. During sleep it can show up as nightmares or damp sheets instead; see GLP-1s and nightmares. Severe episodes can progress to an inability to treat yourself, which is what the label means by requiring another person’s assistance. A racing heart without those other signs has other explanations on these drugs, covered in GLP-1 heart rate and palpitations. Because the labels list anxiety among these signs, an episode can be mistaken for a panic attack; see GLP-1s and anxiety.

There is a wrinkle specific to these drugs. GLP-1 medicines slow how quickly the stomach empties, which is also how quickly a fast-acting carbohydrate reaches the bloodstream. That does not change what you should do about a low reading, but it is a reason to raise the question with whoever manages your diabetes, since the usual timing assumptions may not hold. A fast long enough to matter changes that arithmetic, and the only place it has been studied is Ramadan. What the four Ramadan studies actually tested is narrower than it is usually reported to be.

Frequently Asked Questions

On their own, rarely. These drugs prompt insulin release in response to glucose, so the effect largely stands down when glucose is normal. The label still counted hypoglycemia below 54 mg/dL in more treated patients than placebo in its type 2 diabetes trial, including one severe episode requiring another person's assistance.
That is where the risk is. The label records a higher rate of hypoglycemia once a sulfonylurea or insulin is also being taken, asks prescribers to weigh a reduction in that other dose as the GLP-1 begins, and asks for glucose monitoring both before and during treatment.
The label does not say it is unsafe; it says the use of Wegovy in type 1 diabetes, or in combination with insulin, has not been evaluated. That is untested rather than prohibited, and it means anyone in that situation is outside what Wegovy's own trials examined. Ozempic and Mounjaro, at diabetes doses, were tested added to basal insulin in type 2 diabetes.
Possibly, but only your prescriber can say by how much. The label asks them to consider a reduction at initiation without naming a figure, because it depends on the drug, the dose and your own readings. Raise it before the first injection rather than after a low reading.
It may affect timing, since these drugs slow how fast the stomach empties and therefore how fast a fast-acting carbohydrate is absorbed. It does not change that a low needs treating. Ask whoever manages your diabetes how it changes the usual advice for you.

References

  1. 1.Novo Nordisk Inc. WEGOVY (semaglutide) — US Prescribing Information, Section 5.4 Hypoglycemia and Section 7.1 Drug Interactions (revised 06/2026) DailyMed (FDA-approved labeling). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
  2. 2.Nong K, Jeppesen BT, Shi Q, et al. Medications for adults with type 2 diabetes: a living systematic review and network meta-analysis BMJ. 2025. PMID: 40813122.
  3. 3.Novo Nordisk Inc. OZEMPIC (semaglutide) injection: US Prescribing Information, Sections 6.1 and 14 (combination with basal insulin) DailyMed (FDA-approved labeling). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79
  4. 4.Eli Lilly and Company MOUNJARO (tirzepatide) injection: US Prescribing Information, Sections 6.1 and 14 (SURPASS-5, added to basal insulin) DailyMed (FDA-approved labeling). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0

Stopping Ozempic or Wegovy: Side Effects, Weight Regain and Keeping It Off

Stopping Ozempic or Wegovy causes no withdrawal syndrome on either label. Appetite returns as semaglutide clears over about five weeks, and a 2026 BMJ meta-analysis found regain of about 0.8 kg a month. What helps keep weight off, and what women should know.

10 min read

GLP-1 Drugs and Suicidal Thoughts: The Warning Came Off in 2026

In February 2026 the Suicidal Behavior and Ideation section was removed from the Wegovy, Zepbound and Saxenda labels, after three large studies looked for a signal and none found one.

7 min read

Exenatide (Byetta, Bydureon): The First GLP-1, Its Weight Loss and Where It Went

Exenatide, sold as Byetta and Bydureon BCise, was the first GLP-1 drug. It is approved only for type 2 diabetes, produces far less weight loss than semaglutide, and both brands are discontinued in the US. Its one generic is now listed as discontinued too.

10 min read

GLP-1 Drugs and Your Kidneys: Protective Over Years, Risky Over Days

Semaglutide cut the risk of kidney failure, a large drop in kidney function, or death from a kidney or cardiovascular cause by 24% over a median 3.4 years. The label also warns of acute kidney injury in people dehydrated by vomiting or diarrhea. Both are true.

7 min read

Injection Site Reactions: Where Semaglutide and Tirzepatide Really Differ

Semaglutide produced injection site reactions in 1.4% against 1% on placebo. Tirzepatide runs 6–8% against 2%. If you react on one and not the other, that is not your technique.

5 min read

GLP-1 Pancreatitis and Gallbladder Risk: What the Labels Counted

Two labeled warnings that are not the same kind of problem. Gallbladder disease tracks with rapid weight loss and is well counted; pancreatitis is rarer, was an exclusion criterion in the pivotal trials, and the database studies disagree.

12 min read

Where to get semaglutide online, safely: sellers our editors have checked

These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.

No insurance needed · vetted by our editors

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

8.2

bmiMD

Starting below a standard dose, with microdose tiers

6.3

WellMedRx

Comparing compounded and brand GLP-1 plans with a published state list

About this analysis

GLP Watchdog publishes independently. Each seller in our dataset is checked against that seller's own website, and the dataset is updated continuously. Read our full methodology →